HOME >> MEDICINE >> NEWS
Effective government/industry collaboration bolsters flu vaccine supply

When faced with an urgent public health need, the federal government, vaccine manufacturers and university-based researchers can work together quickly and effectively to come up with solutions, as demonstrated in the successful clinical trial of the influenza vaccine Fluarix. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), working closely with the Food and Drug Administration (FDA), sponsored the clinical trial that demonstrated the vaccine's safety and ability to generate an immune response and ultimately led to its expedited approval by FDA in August 2005. Fluarix is the first vaccine to receive FDA approval under the agency's accelerated approval regulations.

Details of the Fluarix clinical study are discussed in the November/December 2005 issue of Human Vaccines, available online December 22.

Clinical testing of the seasonal influenza vaccine Fluarix began in December 2004 as an effort to augment the future U.S. flu vaccine supply, which was experiencing an unexpected, significant shortage. Fluarix, which is manufactured by GlaxoSmithKline Biologicals of Rixensart, Belgium, had been approved in 1998 for use in other countries but had never been tested or licensed for use in the United States.

The vaccine was evaluated in a clinical trial involving nearly 1,000 healthy adults at four sites nationwide. Clinical evaluation of the candidate vaccine was performed under an FDA-reviewed "investigational new drug" application, in which potential study volunteers are fully informed about potential risks and benefits and must provide their informed consent before receiving the investigational product. The clinical trial was rapidly initiated and reached capacity enrollment within five days of its launch in December 2004.

"The Fluarix study is an excellent example of what government and industry can accomplish in a short timeframe when faced with a serious public health nee
'"/>

Contact: Kathy Stover
kstover@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
22-Dec-2005


Page: 1 2 3

Related medicine news :

1. Effectiveness of first renin inhibitor drug for treating hypertension is limited
2. Effectiveness of over-the-counter decongestant questioned in new study
3. Effective medical response reduced deaths of critically injured after London bombings
4. Effective HIV control may depend on viral protein targeted by immune cells
5. Effective treatments for panic disorder not reaching patients
6. Effective alcohol dependence treatments defined
7. Effective treatment of a mothers depression reduces risk of psychiatric disorders in her children
8. Effective hospital patient handoffs require better training for physicians
9. Acrux and Oreganon further expand their collaboration
10. Asia-European collaboration addresses water management in Indonesia
11. Penn leads $98 million translational medicine collaboration

Post Your Comments:
(Date:10/31/2014)... for low back pain caused by spinal stenosis varies ... a new report says. "Nearly 80 percent of ... in their lives, and about 30 million people a ... co-author Brook Martin, of the Dartmouth Institute of Health ... release. In spinal stenosis, thickening of tissue surrounding ...
(Date:10/31/2014)... IL – New research suggests that insomnia is a ... and other unintentional fatal injuries. The results underscore the ... the National Healthy Sleep Awareness Project. , Results show ... a dose-dependent manner with the number of insomnia symptoms ... 2.8 times more likely to die from a fatal ...
(Date:10/31/2014)... The Suspension Revolution review published by Daily Gossip ... Dan Long, a suspension training specialist. , Long ... life coach. The author of this program claims that ... impossible , The Suspension Revolution review reveals that this ... efficiency when it comes to burning fat, building muscles, ...
(Date:10/31/2014)... Florida Air Academy, the Melbourne ... grades 6-12, is taking the lead when it ... concussions, becoming the first high school in central ... Assessment and Cognitive Testing) computerized assessment to all ... grabs the headlines, and the Centers for Disease ...
(Date:10/31/2014)... Phoenix dentist , Dr. Christy, is ... Whether patients simply need routine care or have a more ... now to get that necessary care. The right dental treatments ... and even essential treatments due to financial concerns. Throughout the ... any treatments offered by the team at Christy Dental Care. ...
Breaking Medicine News(10 mins):Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... ARBOR, Mich. , Oct. 31, 2014 /PRNewswire/ ... immune modulators to treat autoimmune disease and cancer, ... of novel synthetic RORgamma agonist product candidates will ... Society for Immunotherapy of Cancer (SITC) being held ... & Convention Center, National Harbor, MD.  The poster, ...
(Date:10/31/2014)... 31, 2014 ThynkWare ( www.thynkware.com ) is ... text and email messages using their thoughts. ... by ThynkWare,s founder, Duane Cash , which is ... This technology allows users to control their devices in ... thought. ThynkWare provides the interface layer between ...
Breaking Medicine Technology:Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2
Cached News: